Programmed intermittent epidural bolus versus continuous epidural infusion for postoperative analgesia after major abdominal and gynecological cancer surgery: a randomized, triple-blinded clinical trial

Continuous epidural infusion (CEI) is the standard application setting for epidural infusion. A new mode, the programmed intermittent epidural bolus (PIEB) technique, showed reduced local anesthetic (LA) consumption and improved analgesia in obstetric analgesia. Goal of this trial was to evaluate th...

Full description

Saved in:

Bibliographic Details
Published in:	BMC anesthesiology Vol. 18; no. 1; p. 154
Main Authors:	Wiesmann, Thomas, Hoff, Lilli, Prien, Lara, Torossian, Alexander, Eberhart, Leopold, Wulf, Hinnerk, Feldmann, Carsten
Format:	Journal Article
Language:	English
Published:	England BioMed Central Ltd 30-10-2018 BioMed Central BMC
Subjects:	Abdominal Neoplasms - surgery Adult Aged Analgesia, Epidural - methods Analgesia, Patient-Controlled - methods Anesthetics, Local - administration & dosage Double-Blind Method Female Gynecologic Surgical Procedures - methods Humans Male Middle Aged Pain Measurement Pain, Postoperative - drug therapy Ropivacaine - administration & dosage
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Continuous epidural infusion (CEI) is the standard application setting for epidural infusion. A new mode, the programmed intermittent epidural bolus (PIEB) technique, showed reduced local anesthetic (LA) consumption and improved analgesia in obstetric analgesia. Goal of this trial was to evaluate the effects of PIEB versus CEI [combined with patient-controlled bolus (PCEA)] on LA consumption and pain scorings in major abdominal cancer surgery. Following ethical approval, patients scheduled for major abdominal cancer surgery under general anesthesia in combination with epidural analgesia were randomized to receive either a PIEB mode of 6 mL/h or a CEI mode set at 6 mL/h of ropivacaine 0.2%, both combined with a PCEA mode set at a 4 mL bolus. LA consumptions and pain scorings were documented until the second postoperative evening. Eighty-four datasets were analyzed (CEI: n = 40, PIEB: n = 44). Regarding the primary endpoint, cumulative LA PCEA bolus volumes until day 2 differed significantly between the groups [PIEB 10 mL (2-28 mL) versus CEI, 28 mL (12-64 mL), median (25th-75th percentiles), p = 0.002]. Overall, LA consumption volumes were significantly lower in the PIEB group versus in the CEI group [PIEB: 329 mL (291-341 mL) vs. CEI: 350 mL (327-381 mL), p = 0.003]. Pain scores were comparable at each time point. This trial demonstrates reduced needs for PCEA bolus in the PIEB group. There were no clinically relevant benefits regarding morphine consumption, pain scorings, or other secondary outcome parameters. This study has been registered retrospectively in the ClinicalTrials.gov registry ( NCT03378804 ), date of registration: December, 20th 2017.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23
ISSN:	1471-2253 1471-2253
DOI:	10.1186/s12871-018-0613-6